Arabinogalactan from Ixeris chinensis (Thunb.) Nakai as a stabilizer to decorate SeNPs and enhance their anti-hepatocellular carcinoma activity via the mitochondrial pathway. Issue 5 (13th June 2022)

• Record Type: Journal Article
• Authors: Li, Hongyan; Wang, Yifan; Chen, Yan; Wang, Shuxin; Zhao, Yifan; Sun, Jinyuan
• Is Part Of: Journal of carbohydrate chemistry. Volume 41:Issue 5(2022)
• Page Start: 329
• Page End: 345
• Publication Date: 2022-06-13
• Subjects: Anti-hepatocellular carcinoma effect -- apoptosis -- arabinogalactan -- SeNPs; Carbohydrates -- Periodicals; 547.78
• DOI: 10.1080/07328303.2022.2105860
• Languages: English
• ISSNs: 0732-8303

Abstract

Abstract: Arabinogalactan (ICPA) was isolated from the medicinal plant Ixeris chinensis (Thunb.) Nakai, and was used as the reducing agent to stabilize selenium nanoparticles (SeNPs). ICPA-decorated SeNPs (ICPA-SeNPs) were synthesized with Na2 SeO3 and ICPA, and their average diameter was 82.6 ± 2.5 nm. ICPA-SeNPs had good dispersity in phosphate-buffered saline (PBS) with a hydrodynamic size of 156.2 ± 2.8 nm. They were stable in PBS solution with a zeta potential of −24.8 ± 0.6 mV. The anti-hepatoma activity of ICPA-SeNPs was investigated in vitro . ICPA-SeNPs significantly suppressed the growth of SMMC-7721 and HepG2 hepatoma cells. They entered SMMC-7721 cells via energy- and caveolae-dependent endocytosis. ICPA-SeNPs were able to increase reactive oxygen species levels, reduce mitochondrial membrane potential, and increase caspase-3 expression in SMMC-7721 cells, which led to the apoptosis of SMMC-7721 cells. They also arrested the cell cycle of SMMC-7721 cells in the S phase. These findings indicate that ICPA could enhance the stability of SeNPs and inhibit SMMC-7721 cell proliferation via the mitochondrial pathway. ICPA-SeNPs could be developed as an antitumor agent for hepatocellular carcinoma treatment.